Dr. Joseph Kozikowski to serve in Chief Medical Officer and Vice President roles for a Canadian emerging leader in molecular imaging.
FRAMINGHAM, MA – January 12, 2004 – Clinivation, Inc. announced today that clinivation Founder and CEO Joseph Kozikowski, M.D. has been appointed Chief Medical Officer and Vice President for ART Advanced Research Technologies Inc. (Toronto Stock Exchange (TSX): ARA.TO), with headquarters in Technoparc Saint-Laurent, Montreal, Canada.
In this role, Dr. Kozikowski will lead and support certain medical, product development, regulatory, and business development initiatives for ART’s clinical molecular imaging systems.
Quotes & Commentary:
“It is an honor and my pleasure to serve ART in this important role, and I thank ART Chief Executive Micheline Bouchard and the ART Board of Directors for their vision and support,” said clinivation Founder and CEO Joseph Kozikowski, M.D.
About ART Advanced Research Technologies:
ART Advanced Research Technologies Inc. is a leader in optical molecular imaging and is dedicated to the development of state-of-the-art technological applications for the life sciences sector. ART has developed two devices based on this innovative technology. The first is eXplore OptixTM, a molecular imaging device designed for monitoring physiological changes in living systems at the pre-clinical study phases of new drugs. eXplore OptixTM is distributed worldwide by GE Medical Systems. The second is SoftScan(R), a medical imaging device designed to detect and characterize breast cancer lesions, and that is intended to be used for the analysis of breast cancer lesions and the monitoring of treatments. ART’s shares are listed on the TSX under the ticker symbol ARA. For more information about ART, visit the web site at www.art.ca.
